Caladrius

Caladrius Biosciences, Inc. (Caladrius, formerly NeoStem) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.
Company Growth (employees)
Type
Public
HQ
Allendale, US
Founded
2006
Size (employees)
221 (est)
Caladrius was founded in 2006 and is headquartered in Allendale, US

Caladrius Office Locations

Caladrius has offices in Allendale and Mountain View
Allendale, US (HQ)
4 Pearl Ct
Mountain View, US
291 N Bernardo Ave

Caladrius Data and Metrics

Caladrius Financial Metrics

Caladrius's revenue was reported to be $35.3 m in 2016
USD

Revenue (Y, 2016)

35.3 m

Revenue growth (Y, 2015 - Y, 2016), %

57%

Gross profit (Y, 2016)

4.1 m

Gross profit margin (Y, 2016), %

12%

Net income (Y, 2016)

(33.3 m)

EBIT (Y, 2016)

(31.3 m)

Market capitalization (22-Jun-2017)

38.3 m

Closing share price (22-Jun-2017)

4.2

Cash (31-Dec-2016)

14.7 m

EV

24.1 m
Caladrius's current market capitalization is $38.3 m.
USDFY, 2013FY, 2014FY, 2015Y, 2016

Revenue

14.7 m17.9 m22.5 m35.3 m

Revenue growth, %

22%25%57%

Cost of goods sold

12.9 m15.7 m20.2 m31.1 m

Gross profit

1.7 m2.3 m2.3 m4.1 m

Gross profit Margin, %

12%13%10%12%

EBIT

(36.8 m)(57.7 m)(113.8 m)(31.3 m)

EBIT margin, %

(251%)(322%)(506%)(89%)

Net Income

(39.5 m)(55.5 m)(81 m)(33.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

46.1 m19.2 m20.3 m14.7 m

Inventories

1.3 m

Current Assets

50.8 m36.3 m29.3 m24.6 m

PP&E

12.8 m16 m17.1 m17.1 m

Goodwill

11.1 m25.2 m7 m7 m

Total Assets

89.8 m126.3 m57.2 m51.8 m

Accounts Payable

3.4 m5.7 m4.1 m4.4 m

Total Debt

3.4 m2.4 m584.4 k

Current Liabilities

9.8 m16.2 m21 m19.5 m

Additional Paid-in Capital

299.6 m350.4 m396.5 m410.4 m

Retained Earnings

(236.4 m)(291.2 m)(372.1 m)(404.8 m)

Total Equity

62 m58.1 m23.3 m4.1 m

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.4 x2.2 x2.5 x12.7 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(39.5 m)(55.5 m)(81 m)(33.3 m)

Depreciation and Amortization

1.6 m2.2 m2.7 m2.7 m

Accounts Receivable

(573 k)(1.2 m)545.2 k(325.6 k)

Inventories

(758.8 k)(2.8 m)

Cash From Operating Activities

(27.1 m)(46.9 m)(39.3 m)(23.7 m)

Purchases of PP&E

(2.7 m)3.7 m3.2 m(2.8 m)

Cash From Investing Activities

(2.7 m)(10.7 m)3.8 m(2.8 m)

Long-term Borrowings

(9.3 m)

Cash From Financing Activities

62.2 m30.7 m36.6 m20.9 m

Interest Paid

274.1 k232.5 k1.5 m1.8 m
Y, 2016

EV/EBIT

-0.8 x

EV/CFO

-1 x

Debt/Equity

0.1 x

Financial Leverage

12.7 x

Caladrius Online and Social Media Presence

Caladrius Company Life and Culture

You may also be interested in